Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.

Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S.

Diabetes Obes Metab. 2019 Jul 12. doi: 10.1111/dom.13830. [Epub ahead of print]

PMID:
31297947
2.

Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme.

Khunti K, Ji L, Medina J, Surmont F, Kosiborod M.

Diabetes Obes Metab. 2019 Jun 19. doi: 10.1111/dom.13817. [Epub ahead of print] Review.

PMID:
31215715
3.

Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.

Pintat S, Fenici P, Hammar N, Ji L, Khunti K, Medina J, Tang F, Wittbrodt E, Surmont F.

BMJ Open Diabetes Res Care. 2019 Mar 21;7(1):e000627. doi: 10.1136/bmjdrc-2018-000627. eCollection 2019.

4.

Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015.

Tabesh M, Magliano DJ, Tanamas SK, Surmont F, Bahendeka S, Chiang CE, Elgart JF, Gagliardino JJ, Kalra S, Krishnamoorthy S, Luk A, Maegawa H, Motala AA, Pirie F, Ramachandran A, Tayeb K, Vikulova O, Wong J, Shaw JE.

Acta Diabetol. 2019 Aug;56(8):889-897. doi: 10.1007/s00592-018-01284-4. Epub 2019 Apr 8.

PMID:
30963308
5.

Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.

Gomes MB, Rathmann W, Charbonnel B, Khunti K, Kosiborod M, Nicolucci A, Pocock SJ, Shestakova MV, Shimomura I, Tang F, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Ji L; DISCOVER investigators.

Diabetes Res Clin Pract. 2019 May;151:20-32. doi: 10.1016/j.diabres.2019.03.024. Epub 2019 Mar 20.

6.

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).

Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Khunti K; DISCOVER investigators.

Cardiovasc Diabetol. 2018 Nov 28;17(1):150. doi: 10.1186/s12933-018-0787-8.

7.

Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015.

Tabesh M, Magliano DJ, Tanamas SK, Surmont F, Bahendeka S, Chiang CE, Elgart JF, Gagliardino JJ, Kalra S, Krishnamoorthy S, Luk A, Maegawa H, Motala AA, Pirie F, Ramachandran A, Tayeb K, Vikulova O, Wong J, Shaw JE.

Diabet Med. 2019 Jul;36(7):878-887. doi: 10.1111/dme.13858. Epub 2018 Nov 21.

8.

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.

Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11.

9.

Prevalence and impact of respiratory symptoms in a population of patients with COPD in Latin America: The LASSYC observational study.

Miravitlles M, Menezes A, López Varela MV, Casas A, Ugalde L, Ramirez-Venegas A, Mendoza L, López A, Wehrmeister FC, Surmont F, Montes de Oca M.

Respir Med. 2018 Jan;134:62-69. doi: 10.1016/j.rmed.2017.11.018. Epub 2017 Nov 28.

PMID:
29413510
10.

Adherence to inhaled therapies of COPD patients from seven Latin American countries: The LASSYC study.

Montes de Oca M, Menezes A, Wehrmeister FC, Lopez Varela MV, Casas A, Ugalde L, Ramirez-Venegas A, Mendoza L, López A, Surmont F, Miravitlles M.

PLoS One. 2017 Nov 15;12(11):e0186777. doi: 10.1371/journal.pone.0186777. eCollection 2017.

11.

Smoke, Biomass Exposure, and COPD Risk in the Primary Care Setting: The PUMA Study.

Montes de Oca M, Zabert G, Moreno D, Laucho-Contreras ME, Lopez Varela MV, Surmont F.

Respir Care. 2017 Aug;62(8):1058-1066. doi: 10.4187/respcare.05440. Epub 2017 May 30.

12.

Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.

Ji L, Bonnet F, Charbonnel B, Gomes MB, Kosiborod M, Khunti K, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Fenici P, Hammar N, Hashigami K, Macaraeg G, Surmont F, Medina J.

J Diabetes Complications. 2017 Jul;31(7):1188-1196. doi: 10.1016/j.jdiacomp.2017.03.011. Epub 2017 Apr 5.

13.

Exacerbations and health care resource utilization in patients with airflow limitation diseases attending a primary care setting: the PUMA study.

Montes de Oca M, Aguirre C, Lopez Varela MV, Laucho-Contreras ME, Casas A, Surmont F.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 7;11:3059-3067. eCollection 2016.

14.

Bronchodilator treatment for COPD in primary care of four Latin America countries: The multinational, cross-sectional, non-interventional PUMA study.

Montes de Oca M, Lopez Varela MV, Jardim J, Stirvulov R, Surmont F.

Pulm Pharmacol Ther. 2016 Jun;38:10-6. doi: 10.1016/j.pupt.2016.04.002. Epub 2016 Apr 23.

PMID:
27113029
15.

Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009-2011.

Verhaegen J, Flamaing J, De Backer W, Delaere B, Van Herck K, Surmont F, Van Laethem Y, Van Damme P, Peetermans W.

Euro Surveill. 2014 Aug 7;19(31):14-22.

16.

Pneumococcal aetiology and serotype distribution in paediatric community-acquired pneumonia.

De Schutter I, Vergison A, Tuerlinckx D, Raes M, Smet J, Smeesters PR, Verhaegen J, Mascart F, Surmont F, Malfroot A.

PLoS One. 2014 Feb 18;9(2):e89013. doi: 10.1371/journal.pone.0089013. eCollection 2014.

17.

Evaluation of a WHO-validated serotype-specific serological assay for the diagnosis of pneumococcal etiology in children with community-acquired pneumonia.

Tuerlinckx D, Smet J, De Schutter I, Jamart J, Vergison A, Raes M, Smeesters PR, Verhaegen J, Surmont F, Malfroot A, Mascart F.

Pediatr Infect Dis J. 2013 Jul;32(7):e277-84. doi: 10.1097/INF.0b013e31828c363f.

PMID:
23407099
18.

Urinary excretion of ephedrine after nasal application in healthy volunteers.

Lefebvre RA, Surmont F, Bouckaert J, Moerman E.

J Pharm Pharmacol. 1992 Aug;44(8):672-5.

PMID:
1359093

Supplemental Content

Loading ...
Support Center